Alembic Pharmaceuticals Limited (APLLTD) — Announcement

· NSE ✨ Positive
📢 Key Event
Alembic Pharmaceuticals receives USFDA final approval for Tretinoin Cream USP, 0.05%
💡 Investor Takeaway
Investors gain confidence in Alembic's expanding US generic pipeline and potential revenue growth from a high‑value dermatology product.

Alembic Pharmaceuticals announced that the USFDA granted final approval for its Tretinoin Cream USP, 0.05% ANDA, a therapeutically equivalent generic to Retin-A Cream indicated for acne vulgaris. The product targets an estimated US$ 76 million market and marks the company's 242nd USFDA approval, including 222 final approvals. This regulatory milestone strengthens Alembic's US generic portfolio and expands its presence in a key therapeutic area.

📄 View Original Announcement (PDF)

About Alembic Pharmaceuticals Limited (APLLTD)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹15,412.51 Cr P/E: 22.9 ROE: 11.8% ROCE: 11.2%

View full APLLTD stock details →

📡 Get AI alerts when APLLTD files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track APLLTD — Free

📊 More APLLTD filings

See all APLLTD filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when APLLTD files new disclosures

Track APLLTD filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track APLLTD — Free

Free account · 2 AI queries/day